MarketLens

Pricing Plans Sign Up Log in

Stock Analysis Investment Ideas Pro

Is Gilead's GH31 Acquisition a Game-Changer for Its Oncology Pipeline

3 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Has Pfizer's Seagen Acquisition Reshaped the Oncology Landscape

4 weeks ago

Is Herbalife's Bioniq Acquisition a Game-Changer for its Personalized Nutrition Strategy

1 months ago

Why Did Gilead Pay $7.8 Billion for Arcellx

3 months ago

Is Brookfield's $1.2 Billion World Freight Acquisition a Game Changer

1 day ago

GH Research: Rapid Onset And Short Action Change The Treatment Paradigm

GH Research is advancing its inhalable mebufotenin therapy, GH001, for treatment-resistant depression following strong Phase 2b results. The company plans to initiate a global Phase 3 program in 2026 ...

GHRS

News•1 week ago

The Cancer Test That Wall Street Is Betting On

A diagnostic company has established an early market lead in blood-based cancer recurrence testing. This technology aims to detect returning cancer in survivors, positioning the firm as a potential le...

Stock News•1 week ago

Gilead's Transition Into A Long-Duration Biotech Platform

Gilead Sciences shares rose 34% as the company transitioned into a diversified therapeutic platform. HIV revenue grew 10% YoY, bolstered by Yeztugo’s $1B guidance, while oncology revenue climbed 37% Y...

GILD

Stock News•4 weeks ago

Eli Lilly to Buy Ajax Therapeutics for Up to $2.3 Billion

Eli Lilly agreed to acquire Ajax Therapeutics for up to $2.3 billion to expand its oncology pipeline. The deal strengthens the drugmaker's blood-cancer portfolio as it continues an aggressive series o...

LLY